NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ:NTHI
Want to see NTHI full AI Analyst Report?
NTHI Stock Chart & Stats
$8.88
--
Market closed
$8.88
--
Day’s Range― - ―
52-Week Range$3.20 - $12.99
Previous CloseN/A
VolumeN/A
Average Volume (3M)103.40K
Market Cap
$138.91M
Enterprise Value$109.78M
Total Cash (Recent Filing)$138.60K
Total Debt (Recent Filing)$346.05K
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Aug 25, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding26,013,136
10 Day Avg. Volume39,098
30 Day Avg. Volume103,402
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-9.07
Price to Sales (P/S)3973.02
P/FCF Ratio-7.62
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.43K
Enterprise Value/Ebitda-3.17
Forecast
1Y Price Target
$16.00Price Target Upside80.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical De-risking (NEO212 RP2D)Completion of NEO212 Phase 1 with a recommended Phase 2 dose and early efficacy signals materially reduces program risk. This validates the oral bioconjugation platform, enables a defined Phase 2 pathway, and strengthens the company’s negotiating leverage with regulators and partners over the medium term.
Established Capital Access (ATM)A $75 million at-the-market program provides scalable, on-demand funding optionality without fixed commitments. Coupled with recent PIPEs and a credit line, this structural financing flexibility helps manage future trial funding needs and reduces the urgency of one-off dilutive financings over the next several quarters.
Strengthened Finance LeadershipHiring an experienced CAO focused on SEC reporting and internal controls is a durable governance improvement. Stronger finance infrastructure supports compliance, scalable expense controls, and investor confidence as the firm advances trials and pursues additional public financings or partnerships.
Bears Say
Zero TTM RevenueNo product revenue means the business is fully pre-commercial and dependent on financing to sustain operations. Without commercialization, revenue generation remains uncertain; the company must convert clinical progress to reimbursable therapies to achieve self-sustaining cash flow beyond the next funding cycles.
Negative Shareholders' EquityNegative equity is a structural capital weakness that limits flexibility and increases dependence on equity raises or debt. It heightens investor sensitivity to dilution and constrains strategic options (M&A, partnerships, licensing) because balance sheet remediation must accompany growth investments.
High Cash BurnSustained ~-$21.7M annual cash burn requires ongoing external funding to progress trials. This persistent negative cash generation elevates refinancing and dilution risk, and places pressure on management to prioritize capital-efficient trial design or secure non-dilutive partnerships to preserve shareholder value.
NeOnc Technologies Holdings, Inc. News
NTHI FAQ
What was NeOnc Technologies Holdings, Inc.’s price range in the past 12 months?
NeOnc Technologies Holdings, Inc. lowest stock price was $3.20 and its highest was $12.99 in the past 12 months.
What is NeOnc Technologies Holdings, Inc.’s market cap?
NeOnc Technologies Holdings, Inc.’s market cap is $138.91M.
When is NeOnc Technologies Holdings, Inc.’s upcoming earnings report date?
NeOnc Technologies Holdings, Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 96 days.
How were NeOnc Technologies Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is NeOnc Technologies Holdings, Inc. overvalued?
According to Wall Street analysts NeOnc Technologies Holdings, Inc.’s price is currently Undervalued.
Does NeOnc Technologies Holdings, Inc. pay dividends?
NeOnc Technologies Holdings, Inc. does not currently pay dividends.
What is NeOnc Technologies Holdings, Inc.’s EPS estimate?
NeOnc Technologies Holdings, Inc.’s EPS estimate is -0.16.
How many shares outstanding does NeOnc Technologies Holdings, Inc. have?
NeOnc Technologies Holdings, Inc. has 26,013,136 shares outstanding.
What happened to NeOnc Technologies Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NeOnc Technologies Holdings, Inc.?
Currently, no hedge funds are holding shares in NTHI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeOnc Technologies Holdings, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (80.18% Upside)
$16.00 (80.18% Upside)
Insider Transactions
Bought Shares
Worth $424.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
284.28%
Trailing 12-Months
Asset Growth
-60.55%
Trailing 12-Months
Company Description
NeOnc Technologies Holdings, Inc.
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
NTHI Stock 12 Month Forecast
Average Price Target
$16.00
▲(80.18% Upside)
Technical Analysis
Ownership Overview
31.23% Insiders
0.85% Mutual Funds
5.90% Other Institutional Investors
61.18% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---